2024–2025年美国猴痘病毒监测
研究分析美国2024–2025年猴痘病毒(MPXV)病例趋势,2024年报告2803例(含1例旅行相关Ib分支),2025年报告2519例(含10例Ib分支);860例完整信息中,未接种者住院 odds 为完全接种者的9.73倍(控制年龄组和HIV状态)。
要点
- 未接种者住院 odds 为完全接种者的9.73倍(控制年龄组和HIV状态)。
- 建议高危人群(含前往持续传播国家的旅行者)完成2剂疫苗接种。
核心结论
- 未接种疫苗者住院 odds 显著高于完全接种者,完成推荐2剂疫苗接种可降低重症和住院风险。
研究设计与样本
- 基于One CDC Data Platform和国家法定报告疾病监测系统(NNDSS)数据的监测分析。
- 分析2024–2025年美国报告MPXV感染病例的趋势和人群特征。
主要发现
- 2024年美国报告2803例MPXV感染,含1例旅行相关Ib分支病例。
- 2025年美国报告2519例,含10例Ib分支病例。
- 患者性别、种族和 ethnicity、性取向、皮损部位和年龄分布与往年相似。
- 860例完整信息中,未接种者住院 odds 为完全接种者的9.73倍(控制年龄组和HIV状态)。
关键数值与推荐
- 推荐高风险MPXV暴露人群(含前往持续Ib或IIb分支传播国家的旅行者)完成2剂疫苗接种系列。
临床怎么用
- 对MPXV暴露高风险人群应鼓励完成推荐2剂疫苗接种,以降低重症和住院风险。
- 持续常规监测有助于限制传播、监测病毒演化变化并将疫苗接种聚焦于受影响地区。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the onset of a global outbreak of monkeypox virus (MPXV) infections in 2022, cases have declined substantially in the United States; however, ongoing low-level transmission has persisted. To assess trends in cases of MPXV infection in the United States during 2024-2025, investigators analyzed data from the One CDC Data Platform and the National Notifiable Diseases Surveillance System. In 2024, a total of 2,803 cases of MPXV infection were reported in the United States, including one travel-associated clade Ib case. In 2025, a total of 2,519 cases were reported, including 10 clade Ib cases. The number of reported cases of MPXV infection during September-October 2025 was double that during the same period in 2024, although cases returned to background levels by the end of December 2025. Demographic characteristics of patients with MPXV infections, including distributions by sex, race and ethnicity, sexual orientation, lesion location, and age, were similar to those reported in previous years. Among 860 patients with complete information, the odds of hospitalization among those who were unvaccinated were 9.73 times those who were fully vaccinated when controlling for age group and HIV status. Encouraging completion of the recommended 2-dose vaccination series for persons at risk for MPXV exposure, including travelers to specific countries with ongoing clade I or clade II transmission, could reduce the risk for severe illness and hospitalization. Continued routine surveillance remains important to limiting future spread, monitoring changes in viral evolution, and focusing vaccination efforts on affected areas.
引用
- Sandford R, Tuttle A, Aeschleman L, et al. Monkeypox Virus Surveillance - United States, 2024-2025. MMWR Morb Mortal Wkly Rep. 2026. PMID: 42623297. doi:10.15585/mmwr.mm7532a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。